TargetBeta
NR3C1
nuclear receptor subfamily 3 group C member 1 · also GR, GRL · Nuclear receptor subfamily 3 group C
17 programs in company-led studies act on NR3C1, from 16 companies: 3 in phase 3, 12 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (16 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 17427 running | – | ChEMBL |
| Budesoniderule | AstraZeneca | phase 4 | 1678 running | – | ChEMBL |
| Prednisonerule | Johnson & Johnson | phase 4 | 658 running | – | ChEMBL |
| Methylprednisolonerule | Pfizer | phase 4 | 235 running | – | ChEMBL |
| Prednisolonerule | Sanofi | phase 4 | 343 running | – | ChEMBL |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 972 running | – | ChEMBL |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 461 running | – | ChEMBL |
| dexamethasone phosphaterule | Eyegate Pharmaceuticals | phase 4 | 211 running | – | ChEMBL |
| vamorolonerule | ReveraGen BioPharma | phase 4 | 111 running | NR3C2 | ChEMBL |
| Triamcinolonerule | Research Insight | phase 4 | 51 running | – | ChEMBL |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 270 running | – | ChEMBL |
| Betamethasonerule | LEO Pharma | phase 4 | 90 running | – | ChEMBL |
| relacorilantrule | Corcept Therapeutics | phase 3 | 223 running | – | ChEMBL |
| Triamcinolone Acetoniderule | Clearside Biomedical | phase 3 | 202 running | – | ChEMBL |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 42 running | AR, PGR | ChEMBL |
| org-34517rule | Pop Test Oncology | phase 2 | 41 running | – | ChEMBL |
| TQC3302 | Sino Biopharmaceutical | phase 1 | 10 running | ADRB2, CHRM3 | the company's pipeline |
Conditions their studies are in
- Asthma, 5 programs
- Pulmonary Disease, Chronic Obstructive, 5 programs
- Cataract, 3 programs
- Macular Edema, 3 programs
- Rhinitis, Allergic, Perennial, 3 programs
- Acne Vulgaris, 2 programs
- Arthritis, Rheumatoid, 2 programs
- Multiple Myeloma, 2 programs
- Prostatic Neoplasms, 2 programs
- Psoriasis, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026Dexamethasone · AbbVie · phase 4 · NCT04973605
- Dec 2026Budesonide · AstraZeneca · phase 4 · NCT07897240
- Dec 2026relacorilant · Corcept Therapeutics · phase 3 · NCT03604198
- Dec 2026Triamcinolone Acetonide · Clearside Biomedical · phase 3 · NCT07832552
- Dec 31, 2026dexamethasone phosphate · Eyegate Pharmaceuticals · phase 4 · NCT07388069
- Dec 31, 2026Triamcinolone · Research Insight · phase 4 · NCT07276802
- Jan 26, 2027fluticasone furoate · GlaxoSmithKline · phase 4 · NCT05757102
- Feb 2027Prednisone · Johnson & Johnson · phase 4 · NCT04411654
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.